For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter.The reported revenue represents a surprise of -4.81% over the Zacks Consensus Estimate of $628.32 million. With the consensus EPS estimate being $0.74, the EPS surprise was -8.11%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

Globus Medical (GMED) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.11%. A quarter ago, it was expected that this medical device company would post earnings of $0.76 per share when it actually produced earnings of $0.84, delivering a surprise of 10.53%.Over the last four quarters ...

Globus Medical (GMED) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to the Globus Medical's First Quarter twenty twenty five Earnings Call. At this time, all lines will be on mute and a Q and A session will be held after the prepared remarks. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. I will now turn the call over to Brian Kearns, S ...

AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our first quarter results were impacted by softer Enabling Tech ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 8. On ...

The first-quarter reporting cycle is off to a positive start, with most companies beating on estimates. However, uncertainty about the overall macroeconomic picture continues to be a significant drag on the earnings outlook as a whole, prompting analysts to cut their estimates for future quarters. Meanwhile, the Medical sector’s earnings growth seems to outshine other sectors significantly. This sector can act as a cushion amid rising volatility across global markets due to increasing tariffs.The key medica ...

AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern T ...

Globus Medical, Inc. (GMED) recently completed its previously disclosed acquisition of Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the treatment of chronic pain.The latest acquisition of Nevro expands Globus Medical's presence in the musculoskeletal market. Potential Trend of GMED Stock Following the NewsSince the announcement on April 03, shares of Globus Medical have dropped 4.6%, closing at $72.02 last Thursday. On a positive note, the company is ...

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to ...

Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from adverse macroeconomic events and intense competition rema ...